GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OraSure Technologies Inc (NAS:OSUR) » Definitions » Cash Conversion Cycle

OraSure Technologies (OraSure Technologies) Cash Conversion Cycle : 161.12 (As of Mar. 2024)


View and export this data going back to 1992. Start your Free Trial

What is OraSure Technologies Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

OraSure Technologies's Days Sales Outstanding for the three months ended in Mar. 2024 was 62.55.
OraSure Technologies's Days Inventory for the three months ended in Mar. 2024 was 137.77.
OraSure Technologies's Days Payable for the three months ended in Mar. 2024 was 39.2.
Therefore, OraSure Technologies's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 161.12.


OraSure Technologies Cash Conversion Cycle Historical Data

The historical data trend for OraSure Technologies's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OraSure Technologies Cash Conversion Cycle Chart

OraSure Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 163.43 153.81 127.94 117.91 121.87

OraSure Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 107.48 166.89 155.86 144.43 161.12

Competitive Comparison of OraSure Technologies's Cash Conversion Cycle

For the Medical Instruments & Supplies subindustry, OraSure Technologies's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OraSure Technologies's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OraSure Technologies's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where OraSure Technologies's Cash Conversion Cycle falls into.



OraSure Technologies Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

OraSure Technologies's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=49.95+111.86-39.94
=121.87

OraSure Technologies's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=62.55+137.77-39.2
=161.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OraSure Technologies  (NAS:OSUR) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


OraSure Technologies Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of OraSure Technologies's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


OraSure Technologies (OraSure Technologies) Business Description

Traded in Other Exchanges
Address
220 East First Street, Bethlehem, PA, USA, 18015
OraSure Technologies is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets most of its sales from the molecular solutions business, derived mainly from customers in the United States.
Executives
Kathleen Gallagher Weber officer: Chief Product Officer 220 EAST FIRST STREET, BETHLEHEM PA 18017
Michele Marie Miller officer: VP, Finance and Controller 220 EAST FIRST STREET, BETHLEHEM PA 18017
Robert W. Mcmahon director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kenneth J Mcgrath officer: Chief Financial Officer C/O ORASURE TECHNOLOGIES, INC., 220 E. FIRST STREET, BETHLEHEM PA 18015
Ronny B Lancaster director ORASURE TECHNOLOGIES INC, 220 EAST FIRST STREET, BETHLEHEM PA 18015
Mara G. Aspinall director 7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Nancy J Gagliano director 33 GRANITE WAY, GRANTHAM NH 03753
Michael Celano director 220 EAST FIRST STREET, BETHLEHEM PA 18015
Manner Carrie Eglinton director, officer: President & CEO C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Scott Gleason officer: Interim CFO/SVP IR 1809 SOUTH 2500 EAST, SALT LAKE CITY UT 84108
Eamonn P Hobbs director C/O DELCATH SYSTEMS, INC., 600 FIFTH AVENUE, NEW YORK NY 10020
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
James A Datin director 21 ESTATES DRIVE, DOYLESTOWN PA 18901
Lelio Marmora director 64 RUE DE VESENEX, DIVONNE LES BAINS I0 01220
Lisa Nibauer officer: President of Diagnostics 1 CRESENT PLACE, SHORT HILLS NJ 07078